Assenagon Asset Management S.A. Makes New $1.89 Million Investment in Prestige Consumer Healthcare Inc. $PBH

Assenagon Asset Management S.A. acquired a new stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) during the 3rd quarter, Holdings Channel reports. The fund acquired 30,286 shares of the company’s stock, valued at approximately $1,890,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Geode Capital Management LLC lifted its holdings in shares of Prestige Consumer Healthcare by 0.7% in the second quarter. Geode Capital Management LLC now owns 1,413,041 shares of the company’s stock valued at $112,843,000 after purchasing an additional 9,455 shares in the last quarter. Congress Asset Management Co. raised its position in Prestige Consumer Healthcare by 1.8% in the 2nd quarter. Congress Asset Management Co. now owns 1,009,595 shares of the company’s stock valued at $80,616,000 after buying an additional 18,015 shares during the last quarter. Westwood Holdings Group Inc. lifted its stake in Prestige Consumer Healthcare by 2.4% in the 2nd quarter. Westwood Holdings Group Inc. now owns 881,908 shares of the company’s stock valued at $70,420,000 after acquiring an additional 20,626 shares in the last quarter. Northern Trust Corp lifted its stake in Prestige Consumer Healthcare by 4.8% in the 1st quarter. Northern Trust Corp now owns 852,274 shares of the company’s stock valued at $73,270,000 after acquiring an additional 39,198 shares in the last quarter. Finally, Bank of America Corp DE boosted its position in Prestige Consumer Healthcare by 19.1% during the 2nd quarter. Bank of America Corp DE now owns 721,371 shares of the company’s stock worth $57,601,000 after acquiring an additional 115,459 shares during the last quarter. 99.95% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Zacks Research upgraded shares of Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a report on Monday, November 10th. Sidoti raised shares of Prestige Consumer Healthcare from a “neutral” rating to a “buy” rating and set a $80.00 target price for the company in a research report on Wednesday, September 24th. Weiss Ratings reiterated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research note on Wednesday, October 8th. Canaccord Genuity Group cut their price target on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating on the stock in a research report on Friday, November 7th. Finally, Jefferies Financial Group decreased their price objective on Prestige Consumer Healthcare from $75.00 to $71.00 and set a “hold” rating for the company in a report on Monday, October 27th. Four equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, Prestige Consumer Healthcare has a consensus rating of “Moderate Buy” and a consensus target price of $85.33.

Prestige Consumer Healthcare Trading Down 0.5%

Shares of Prestige Consumer Healthcare stock opened at $62.34 on Wednesday. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.70 and a quick ratio of 2.51. The business has a fifty day simple moving average of $60.74 and a two-hundred day simple moving average of $67.64. Prestige Consumer Healthcare Inc. has a 1 year low of $57.25 and a 1 year high of $90.04. The company has a market capitalization of $3.00 billion, a price-to-earnings ratio of 15.47, a P/E/G ratio of 1.97 and a beta of 0.39.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings data on Thursday, November 6th. The company reported $1.07 earnings per share for the quarter, beating the consensus estimate of $0.97 by $0.10. The company had revenue of $274.11 million for the quarter, compared to analyst estimates of $257.14 million. Prestige Consumer Healthcare had a net margin of 18.09% and a return on equity of 12.43%. The company’s revenue was down 3.4% on a year-over-year basis. During the same period in the prior year, the firm earned $1.09 earnings per share. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. Research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Insider Transactions at Prestige Consumer Healthcare

In other news, VP Jeffrey Zerillo sold 719 shares of the business’s stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $60.00, for a total transaction of $43,140.00. Following the completion of the sale, the vice president owned 42,329 shares in the company, valued at $2,539,740. The trade was a 1.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.40% of the stock is owned by company insiders.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).